Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Results Enrollment was undertaken between May 18, 2021, and September 8, 2023
What testing does Virtus Peptides run on MT-2
High Gpx1 expression predicts poor survival in laryngeal squamous cell carcinoma
Pros: One of the most extensively studied healing peptides in animal and in vitro models, with a broad published mechanistic literature Reported to have a favorable short-term tolerability profile in the limited human data available, with side effects typically mild and self-limiting Available in both injectable and oral research formulations, offering flexibility for different use cases Cons: No completed Phase 2 or Phase 3 human clinical trials exist
US$ 26.32
US$ 27.23
US$ 28.60
